Saturday 17 October 2026
Export MLEC’s income statement to Excel — free account
Moolec Science SA
MLEC Healthcare Biotechnology
In the quarter to December 2025, revenue grew 948.4%, EPS fell 20.0% and free cash flow grew 4.48%, each against the same quarter a year earlier.
1.68
0.19
−10.16%
Follow MLEC
| Dec '25 | Dec '24 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | (709.95%) | (452.66%) | (25.13%) |
+8 more TTM periods Free account |
|
| 0.00% | (127.71%) | (119.93%) | (6.71%) | ||
ROIC |
0.00% | 52.66% | 50.68% | 1.90% | |
Return on Tangible Assets |
0.00% | (773.67%) | (656.00%) | (38.27%) | |
Average Days of Receivables |
0.00 | 2.13 | 1.27 | 191.21 | |
Free Cash Flow per Share |
0.00 | 69.80 | 72.73 | 37.87 | |
Free Cash Flow |
18.34 | 18.14 | 18.76 | 14.70 | |
Capital Expenditures |
(26.44) | (25.05) | (21.41) | (24.85) | |
| Other line items | |||||
Cash ROIC |
22.19% | 68.12% | 60.12% | 1.91% | |
Accounts Receivable Turnover |
0.00 | 237.93 | 271.64 | 3.79 | |
Accounts Payable Turnover |
0.00 | 74.50 | 53.51 | 3.17 | |
Inventory Turnover |
0.00 | 105.75 | 93.63 | 4.41 | |
Average Days of Payables |
0.00 | 4.05 | 3.50 | 220.72 | |
Days of Inventory on Hand |
0.00 | 6.26 | 7.29 | 164.91 | |
Tax Rate |
— | 0.06 | 0.05 | 0.04 | |
Research and Development Expense of Revenue |
— | 3.68% | 3.75% | 3.74% | |
Selling, General and Administrative Expense of Revenue |
— | 26.77% | 27.03% | 27.09% | |
Share Based Compensation of Revenue |
0.00% | 2.78% | 3.02% | 3.04% | |
Interest Coverage |
— | 0.50 | 0.51 | 0.51 | |
Operating CF/Net income |
0.00 | (1.28) | (1.22) | (1.21) | |
Depreciation/Fixed assets |
4.31 | 14.32 | 14.53 | 0.24 | |
Capex/Depreciation |
(1.41) | (1.38) | (1.19) | (1.39) | |
Revenue per Share |
— | 1,802.94 | 1,806.95 | 1,201.07 | |
Operating CF per Share |
0.00 | 166.18 | 155.72 | 101.87 | |
Capex per Share |
0.00 | (96.38) | (82.99) | (64.01) | |
Capex to Sales |
0.00 | 0.05 | 0.05 | 0.05 |
Columns are period end dates